40 Results for "

p110δ

" in MedChemExpress (MCE) Product Catalog:
Products (40)

40 Results for "p110δ" in MCE Product Catalog:

  • Isoforms Recommended:
1199
1199 Publications Verification
Cat. No.: HY-10108A
CAS No.: 934389-88-5
Purity:  99.93%
Research Areas:  

Cancer

LY294002 hydrochloride is a potent and broad-spectrum PI3K inhibitor, with IC50 values of 0.5, 0.57, and 0.97 μM for P110α, P110δ and P110β, respectively. LY294002 hydrochloride also inhibits CK2 with an IC50 of 98 nM. LY294002 hydrochloride can be used for pancreatic cancer research .
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-70063
CAS No.: 944396-07-0
Synonyms: BKM120; NVP-BKM120
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with blood-brain barrier permeability. Buparlisib has IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively .
loading...
    loading...
90
90 Cited Publications
Cat. No.: HY-15180
CAS No.: 1312445-63-8
Purity:  99.88%
Synonyms: BKM120 Hydrochloride; NVP-BKM120 Hydrochloride
Buparlisib Hydrochloride (BKM120 Hydrochloride) is a CNS-penetrant pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.
loading...
    loading...
71
71 Cited Publications
Cat. No.: HY-50673
CAS No.: 915019-65-7
Synonyms: BEZ235; NVP-BEZ235
Target:  

PI3K mTOR Autophagy

Research Areas:  

Cancer

Dactolisib (BEZ235) is an orally active and dual pan-class I PI3K and mTOR kinase inhibitor with IC50s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR, respectively. Dactolisib (BEZ235) inhibits both mTORC1 and mTORC2.
loading...
    loading...
57
57 Cited Publications
Cat. No.: HY-13026
CAS No.: 870281-82-6
Purity:  99.69%
Synonyms: CAL-101; GS-1101
Target:  

PI3K Autophagy

Research Areas:  

Cancer

Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115
CAS No.: 371935-74-9
Purity:  99.82%
Research Areas:  

Cancer

PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .
loading...
    loading...
33
33 Cited Publications
Cat. No.: HY-10115A
CAS No.: 371935-79-4
Purity:  98.55%
Research Areas:  

Cancer

PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-17044
CAS No.: 1201438-56-3
Synonyms: IPI-145; INK1197
Target:  

PI3K

Research Areas:  

Cancer

Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-15245
CAS No.: 1372540-25-4
Purity:  99.59%
Target:  

PI3K

Research Areas:  

Cancer

GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a Ki of 0.89 nM and an IC50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15900
CAS No.: 934493-76-2
Purity:  99.82%
Synonyms: XL765; SAR245409
Target:  

PI3K mTOR

Research Areas:  

Cancer

Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43?nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150?nM) and mTOR (IC50=157?nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12235
CAS No.: 955977-50-1
Purity:  98.97%
Target:  

PI3K

Research Areas:  

Inflammation/Immunology Cancer

PI-3065 is a potent inhibitor of PI3K p110δ, with IC50 and Ki values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC50s of 910, 600, >10000 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10303
CAS No.: 900185-02-6
Purity:  99.90%
Target:  

PI3K

Research Areas:  

Cancer

PIK-294 is a potent p110δ-selective inhibitor with an IC50 of 10 nM.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N6775
CAS No.: 502632-66-8
Synonyms: PX-866
Target:  

PI3K

Research Areas:  

Cancer

Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13504
CAS No.: 900185-01-5
Purity:  99.41%
Target:  

PI3K

Research Areas:  

Metabolic Disease Cancer

PIK-293, an analog of IC87114, is a PI3K inhibitor, with IC50 values of 0.24 μM, 10 μM, 25 μM and 100 μM for p110δ, p110β, p110γ and p110α, respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-108418
CAS No.: 870281-17-7
Purity:  99.52%
Target:  

PI3K

Research Areas:  

Cancer

PI3Kδ-IN-15 (compound 6b) is a selective PI3Kδ inhibitor with an IC50 of 0.5 nM for p110δ. PI3Kδ-IN-15 inhibits PI3Kδ with >30-fold higher potency than PI3Kγ, PI3Kβ, and PI3Kα .
loading...
    loading...
Cat. No.: HY-109198
CAS No.: 1401436-95-0
Purity:  99.90%
Synonyms: ME-401; PWT-143
Target:  

PI3K Akt

Research Areas:  

Cancer

Zandelisib (ME-401) is a selective, orally active, non-covalent inhibitor of PI3Kδ. Zandelisib can sustainably inhibit AKT phosphorylation and downstream signaling pathways. Zandelisib can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-114428
CAS No.: 1595129-71-7
Purity:  98.44%
Target:  

PI3K

Research Areas:  

Cancer

P110δ-IN-1 is a potent and selective inhibitor of P110δ extracted from patent WO 2014055647 A1, with an IC50 of 8.4 nM .
loading...
    loading...
Cat. No.: HY-156371
CAS No.: 2569296-51-9
Purity:  99.61%
Target:  

PI3K

MIPS-21335 is a PI3KC2α inhibitor with an IC50 of 7 nM. MIPS-21335 also inhibits PI3KC2β, p110α, p110β and p110δ, with IC50 values of 43, 140, 386 and 742 nM, respectively. MIPS-21335 has antithrombotic effect. MIPS-21335 can be used for the researches of cardiovascular disease and metabolic disease, such as thrombosis and hyperlipidemia .
loading...
    loading...
Cat. No.: HY-111184
CAS No.: 901398-68-3
Purity:  99.05%
Target:  

PI3K

Research Areas:  

Cancer

PIK-108 is a non-ATP competitive, allosteric p110β/p110δ selective inhibitor .
loading...
    loading...
Cat. No.: HY-111510
CAS No.: 1425043-73-7
Purity:  99.59%
Target:  

PI3K

Research Areas:  

Inflammation/Immunology

IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC50 of 2.5 ± 1.2 nM.
loading...
    loading...